Answers are grounded in this paper and cite their sources.
Randomized trial evaluates BVS 3 score accuracy in predicting COPD exacerbations through remote monitoring, suggesting improved patient management.
Early detection of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) remains a critical challenge in COPD management. This study introduces the Bora Vital Sign Standard Score (BVS 3 ), a novel unsupervised statistical score that predicts AECOPD using vital signs collected at home through remote patient monitoring, and retrospectively evaluates its predictive performance in identifying AECOPD ahead of clinician-defined episodes. The eMEUSE-SANTÉ clinical trial (NCT04963192) involved 220 COPD patients who were remotely monitored for six months using a CE-certified (Class IIa) connected wristband measuring oxygen saturation (SpO₂), breathing rate (BR) and heart rate (HR). A total of 42 physician validated exacerbations of COPD with no missing remote monitoring data were documented in 39 patients at a general hospital. Continuous 24-hour monitoring of vital signs using a connected wristband was well accepted over the long term, with a median adherence of 86% indicating strong patient compliance. The BVS 3 risk score achieved excellent predictive performance, with an AUC of 0.88 (95% CI 0.83 – 0.92) for moderate and severe AECOPD combined. The BVS 3 score anticipated exacerbations an average of 4.4 ± 3.1 days before clinical confirmation, with an overall accuracy of 84.8% and sensitivity of 74% with 85% specificity. Individual Z-scores for heart rate (z-HR), breathing rate (z-BR) and oxygen saturation (z-SpO 2 ) showed specific predictive capabilities for moderate and severe events, yielding AUCs of 0.83, 0.82 and 0.71 respectively, but with inferior performances compared with the combination of the 3 vital signs Z-scores. These results demonstrate that integrating passive remote monitoring with unsupervised statistical modeling provides a scalable, high-compliance approach to AECOPD detection. The interpretable BVS 3 risk score achieves good accuracy and anticipation for AECOPD prediction with minimal patient burden. By enabling earlier intervention, this end-to-end digital solution could significantly improve patient outcomes through proactive disease management.
No takes yet. Share an insight, caveat, or question.
Tilquin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: